Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bay 11-7085 抑制NF-κB 激活和IκBα磷酸化,其稳定 IκBα 的IC50值为 10 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 247 | 现货 | ||
5 mg | ¥ 455 | 现货 | ||
10 mg | ¥ 638 | 现货 | ||
25 mg | ¥ 1,090 | 现货 | ||
50 mg | ¥ 1,650 | 现货 | ||
100 mg | ¥ 2,460 | 现货 | ||
200 mg | ¥ 3,630 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 449 | 现货 |
产品描述 | Bay 11-7085 can irreversibly inhibit the IκBα phosphorylation induced by TNFα (IC50: 10 μM). |
靶点活性 | IκBα phosphorylation:10 μM |
体外活性 | 在含Caov-3细胞的无胸腺裸鼠体内,BAY 11-7085可使紫杉醇对腹内传播和腹水产生的抑制作用增强.BAY11-7085对脑膜炎相关的NF-κB活性增加有抑制作用,改善被感染大鼠临床状态,并使脑膜炎相关的CNS并发症和脑膜炎症显著衰减. |
体内活性 | BAY 11-7085与紫杉醇联用可增强对NF-κB活性的抑制,并使经紫杉醇处理细胞的存活率降低。通过抑制NF-κB,BAY11-7085可抑制TNFα诱导的粘附分子E-selectin,ICAM-1及VCAM-1的表达。BAY11-7085(10 μM)对HUVEC细胞无细胞毒性。此外,Bay11-7085与LY294002联用可协同影响PEL细胞的凋亡。 |
激酶实验 | In Gel Kinase Assay: In gel kinase assay for the proteins that phosphorylate IκB-α is carried out as detailed below. Whole cell extracts are prepared from HUVEC treated with TNFα (100 units/ml) for 15 min in the presence or absence of inhibitor (20 μM, pretreatment for 1 h) as indicated. Proteins are separated on a 10% SDS gel containing 0.5 mg/ml HIS-IκB-α. Gels are washed two times in 20% propanol, 50 mM Hepes, pH 7.6, for 30 min and two times in buffer A (50 mM Hepes, pH 7.6, 5 mM 2-mercaptoethanol) for 30 min, followed by a 1-h incubation with buffer A containing 6 M urea, 1 h each in 3, 1.5, and 0.75 M urea in buffer A and 0.05% Tween 20 and 1 h in buffer A with 0.05% Tween 20. The kinase assay is carried out for 1 h at 30?°C in the presence of 50 μM ATP, 5 μCi/ml [32P]ATP, 20 mM Hepes, pH 7.6, 20 mM MgCl2, 20 mM β-glycerophosphate, 20 mM p-nitrophenyl phosphate, 1 mM sodium vanadate, 2 mM dithiothreitol. The gel is washed with 5% trichloroacetic acid and 1% sodium pyrophosphate, dried, and exposed to film. A separate gel with no HIS-IκB-α is assayed as a control. |
细胞实验 | Human umbilical vein endothelial cells (HUVEC) are isolated and maintained in culture. Cell toxicity is assessed by morphology and by MTT assay.(Only for Reference) |
别名 | BAY 11-7083 |
分子量 | 249.33 |
分子式 | C13H15NO2S |
CAS No. | 196309-76-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 24.9 mg/mL (100 mM)
Ethanol: 24.9 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 4.0107 mL | 20.0537 mL | 40.1075 mL | 100.2687 mL |
5 mM | 0.8021 mL | 4.0107 mL | 8.0215 mL | 20.0537 mL | |
10 mM | 0.4011 mL | 2.0054 mL | 4.0107 mL | 10.0269 mL | |
20 mM | 0.2005 mL | 1.0027 mL | 2.0054 mL | 5.0134 mL | |
50 mM | 0.0802 mL | 0.4011 mL | 0.8021 mL | 2.0054 mL | |
100 mM | 0.0401 mL | 0.2005 mL | 0.4011 mL | 1.0027 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bay 11-7085 196309-76-9 Apoptosis NF-Κb IκB/IKK Ferroptosis NF-κB BAY 11-7085 BAY 11-7083 inhibit Nuclear factor-κB Inhibitor Bay 11 7085 Bay 117085 Nuclear factor-kappaB inhibitor